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IL-6 (reviewed in references 1-3) is a recently recognized cytokine that is identical
to the 26-kD protein, IFN-R2, B cell-stimulating factor 2, hybridoma growth factor,
and hepatocyte-stimulating factor. Its pleiotropic functions include actions on lym-
phocytes, hepatocytes, and hematopoietic progenitors. It has been shown in vitro
and/or in vivo in mice that LPS, TNF, IL-1, and platelet-derived growth factor can
induce the synthesis and/or release of IL-6.
It is conceivable that IL-6 is the mediator of some of the actions that are observed
after the in vivo administration of TNF or IL-1, such as the induction of at least
part of the acute phase response, and it has been suggested that IL-6 is implicated
in other human diseases such as autoimmune disease.
Consequently, it would be useful to know whether TNF also induces IL-6 in human
patients and, if so, to what extent. Moreover, it would be of interest to know whether
such in vivo synthesis is modulated by other substances, such as IFN-y, which are
synergistic with TNF To that end, we analyzed plasma samples obtained during
phase I clinical trials involving a 24-h continuous infusion of human recombinant
(hr)TNF (4) and of two overlapping, 24-h continuous infusions of hrIFN-y and
hrTNF (5).
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Patients.
￿
Plasma samples of 27 cancer patients were included. 16 patients had been ad-
mitted to the Dana-Farber Cancer Institute (Boston, MA) for treatment during a phase I
clinical trial of hrTNF administered as a 24-h continuous intravenous infusion. Details of
inclusion and exclusion criteria, tumor responses, experimental protocol, toxicity patterns,
and metabolic responses have been reported elsewhere (4, 6). Written consent was obtained
from each patient and the studies were approved by the hospital'sInstitutional Review Board.
The 11 other patients were admitted to the same institute for treatment during another phase
I clinical trial (5) of two overlapping, 24-h continuous infusions comprising a fixed dose of
hrIFN-.y (200 jug/m2) and a variable dose of hrTNF (ranging from 4.5 to 205 ttg/mz); the
latter infusion started 12 h after the onset of the first. Exclusion and inclusion criteria, as
well as treatment conditions, were essentially the same as in the first trial (5). hrTNF was
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obtained from Asahi Chemical Industry, New York, NY, and hrIFN-y from Amgen, Thou-
sand Oaks, CA. The hrTNF infused contained <10 pg endotoxin/mg protein as assessed by
the limulus assay.
Samples.
￿
Blood was sampled with a forearm venous catheter or through direct venipunc-
ture, immediately before the infusion and after 0.5, 1, 3, 6, 12, and 24 h. The samples were
stored as plasma at -80°C. In the case of the combined infusion, blood was sampled im-
mediately before the infusion and after 6, 12, 13, 15, 18, 24, and 36 h (i.e., 12, 6, and 0 h
before the onset of the hrTNF infusion, and 1, 3, 6, 12, and 24 h during the infusion).
Bioassay.
￿
IL-6-dependent mouse hybridoma cells, namely 7TD1 cells (7), were cultured
in flat-bottomed 96-well microtiter plates (7,000 cells/well) in the presence ofmedium, serial
dilutions of plasma, or purified, yeast-expressed hrIL-6 (250 pg/ml) as a standard. After
3 d ofculture, the number of surviving cells was determined by a colorimetric assay for hex-
osaminidase (8). Titers were assigned by comparing dilutions of samples and of the standard
needed to obtain half-maximal growth ofthe hybridoma cells; they are expressed as the loga-
rithmof the concentration in picograms/milliliter. The detection level(half-maximal growth
of 7TD1 cells) for hrIL-6 was 2-4 pg/ml. The detection level of IL-6 in human plasma was,
due to the toxicity of some undiluted plasma samples for the tester cells, arbitrarily set at
40 pg/ml. In some experiments a polyclonal rabbit antiserum raised with yeast-expressed
hrIL-6, purified to near homogeneity (2), was added to test the specificity of the growth
factor activity. The presence of TNF, IFN-y, or IL-1 did not interfere in the assay.
Results
We analyzed plasma from 16 patients receiving a continuous, 24-h infusion of
hrTNF, sampled before the infusion and at various time points during the infusion.
None ofthe plasma samples taken before the infusion contained detectable amounts
of IL-6 (<40 pg/ml). All patients (except for the two receiving the lowest doses of
hrTNF, namely 22 and 45 1~g/m2, where TNF levels were not detected) transiently
had detectable IL-6 levels, the major peak levels being found in plasma collected
after 6 h (n = 12) (Fig. 1). Only two patients showed a peak IL-6 level already
3 h after the onset of the infusion. The time of the peak IL-6 level for each patient
can be seen in Fig. 2. Fig. 1 compares the kinetics of the presence ofTNF and IL-6
detectable in the plasma (results of TNF determinations in patients of this phase
I trial have been published previously [4, 6] and are displayed here only to show
the time relationship with the presence of IL-6). Because ofthe considerable interin-
dividual variation in detectable hrTNF concentrations, levels are shown for a hypothet-
ical average patient calculated as the means from patients over the whole dose range
of hrTNF administered. It can be observed that even during a continuous infusion
of TNF, both cytokines are only transiently detectable in the plasma and that the
wave of detectable TNF precedes the wave of detectable IL-6, which persists for a
somewhat longer time.
The samples containing the peak IL-6 levels were retested in triplicate in one assay
run to exclude interassay variability (Fig. 2). For hrTNF doses between 136 and
545 Ag/m2 , a good correlation exists between the dose of hrTNF and the level of
IL-6 obtained (y = 2 .14 + 0.004 x; r = 0.86; p <0.001). To know if an IL-6 plateau
value is reached with high doses of hrTNF, more patients should be included in the
test. This is, due to the toxicity ofthe treatment, not realistic. Addition ofantiserum
to hrIL-6 completely neutralized the activity in the plasma samples, documenting
the specificity of the bioassay.
We also analyzed plasma samples from 11 patients receiving two overlapping 24-h
infusions of hrIFN-y (fixed dose of 200 ttg/m2) and hrTNF, the latter starting 12 ha
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time after start of hr TNF infusion (h)
FIGURE 1 .
￿
Comparison ofkineticprofiles of detectable IL-6 andTNFduring a24-h continuous
infusion ofhrTNE Values ofdetectable IL-6 andTNFlevels areplottedagainsttime forahypothet-
ical average patienthavinglevels calculated as the meansfrom patients over thewholedose range
of hrTNF administered. Mean IL-6 levels (O) are calculated based on data from 16 patients.
Mean TNF levels (/) are basedon data from 12 patients receivinghrTNF over 24 h, andwere
determined by ELISA. Detailsanddata oftheseTNFdeterminations have been publishedprevi-
ously(4).To calculate themean values,resultsbelowthedetectionlevelwere assigned atheoret-
ical value of halfof the detection level(detection levels are 40 pg/mlforIL-6 [log 40 = 1.6] and
90 pg/ml for TNT). Note that the IL-6 levels (left ordinate) are expressed as the logarithms of
the concentration.
after the onset of the infusion with hrIFN-,y. Before the onset of the infusions with
hrTNF, no IL-6 could be detected, except for two samples containing low values
of IL-6: a plasma sample obtained after 6 h contained 113 pg/ml of IL-6, while a
sample from another patient taken after 12 h contained 59 pg/ml of IL-6. As for
the trial without hrIFN-,y, a transient appearance of IL-6 was detected for all pa-
tients after the onset of the infusion with hrTNF, except for the one who received
the lowest dose of TNF, namely 4.5 /Ag/m2. The samples per patient containing the
peak IL-6 levels were reassayed in the single assay run mentioned above (Fig. 2).
Linear regression analysis also showed a good correlation between the IL-6 values
obtained and thehrTNF dose received in thecombination study(y = 1.644 + 0.012
x; r = 0.96; p < 0.001).
When the results obtained for the second part of this study are compared with
those ofthe first part, two differences can be observed. First, the peak levels of IL-6
recorded fora same dose ofhrTNF are higher in the case of the treatment involving
IFN-,y also. Second, the time of the peak is more variable than in the first series:
1 h (n = 2), 3 h (n = 3), and 6 h (n = 5) after the onsetof the infusion with hrTNF,
the correlation being nil between the time that the peak level is reached and the
dose of hrTNFis given. It should be noted that thelinear regression calculation based
on the first study involving patients receiving hrTNF alone and considering only
a comparable dose range of hrTNF (namely 136-227 wg/m2), yields a regression line
whose slopeis very similarto the one obtained for theresultsfrom patients receiving
the combination ofhrTNF andhrIFN-,y (y = 0.738 + 0.012 x; r = 0.91; p < 0.05).2260
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Correlation between hrTNF dose and peak IL-6 levels. Logarithmic means t SD
of triplicate determinations of peak IL-6 levels for each patient are plotted against the hrTNF
dose administered. Open symbols referto patients whowere treatedwith hrTNF alone(O, peak
level reached at 6h; Q, peak level reached at 3 h afterthe start of the infusion). Alinear regres-
sion wascalculated by the least squares method for the dose rangebetween 136 and 545 wg/m2
(y = 2.14 + 0.004 x; r = 0.86; p < 0.001). Closed symbols refer to patients who were treated
with overlapping infusions of hrIFN-y (fixed dose of 200 ug/m2) and hrTNF (A, peak level
reached after 1 h; /, peak level reached after 3 h; ", peak level reached after 6 h; hours after
thestartoftheinfusion with hrTNF). Linear regression wascalculated forthedose rangebetween
5.45 and 205 pg/m2 (y = 1.644 + 0.012 x; r = 0.96; p < 0.001). A third linear regression was
calculated usingthe IL-6 levels ofpatients receivinghrTNF alone in thedose range between 136
and 227 Kg/m2, i.e., that part of the dose range that is comparable with the hrTNF dose range
of patients receivingthecombination ofhrIFN-y and hrTNF and yielding IL-6 levels above the
detection limit (y = 0.738 + 0.012 x; r = 0.91; p< 0.05).
Discussion
The results show that TNF administered to patients can induce considerable
amounts of IL-6 in the plasma. Consequently, TNF, in addition to its direct effects,
may also indirectly induce an acute phase reaction, activate the immune system,
and exert other pleiotropic activities.
The fact that the appearance of IL-6 in plasma is only transient during a con-
tinuous infusion may be ascribed to two reasons. First, it is possible that the in vivo
inductionof IL-6 by TNF belongs to the burst-like type or that negative feedback-
regulating mechanisms are also induced, either by TNF or by IL-6. Alternatively,
this transient effect could be due to the so far unexplained fact that TNF does not
reach a steady state levelduring continuous infusion (4, 9), but canonly be detected
transiently in the circulation.
The observation of higher levels of IL-6 during the combined infusion test is not
unexpected, sinceIFN-yis synergistic with TNF for othereffects, such as antitumor
activity in mice (10) and other biological activities in this trial (5). The fact that
the regression lines of both treatments had a comparable slope for the lower dose
range of hrTNF could indicate that the mechanism of IL-6 induction is similar in
both cases, and that the higher amounts of IL-6 found in the case of the combinedBROUCKAERT ET AL.
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treatment could be ascribed to a sensitization of the target cells to hrTNF, e.g., by
augmenting the number ofreceptors. Theobservation that this slopeis steeperthan
the one of the overall regression line for the treatment with hrTNF alone makes it
likely that a plateau value of IL-6 would be obtained for higher doses of hrTNF
It has been shown that there is a good correlation between the dose of hrTNF
administered in this trialand thelevel ofC-reactive proteinobtained (6). The present
observation that thereis also agood correlation betweenthehrTNF dose administered
andthe IL-6 level obtained is in accordance with thehypothesis that theacutephase
reaction observed after administration of hrTNF to patients is mediated by IL-6.
It has been proposed that TNF is the agent responsible for endotoxic shock, and
thereis indeed extensive evidence that TNFis anecessarykeyfactor in septic shock
(11). It should be noted, however, that not only after LPS do a number of cytokines
appear in blood, but that this is also the case after THE Hence, it is conceivable
that the shock observed after LPS, which can be mimicked by TNF in animals, is
the result of acomplex interplay ofdifferent cytokines. The synergistic/antagonistic
effects of these induced cytokines (like IL-1 and IL-6) in different clinical situations
remain to be evaluated. Recent results in animal models indeed suggest asynergistic
role for IL-1 in endotoxic shock (12), whereas our preliminary results in mice do
not show an enhancement of toxicity by IL-6.
Summary
Plasma samples obtained from patients receiving a 24-h continuous infusion of
human recombinant(hr)TNF or acombination oftwo overlapping, 24-h continuous
infusions of hrIFN-y and hrTNF were analyzed for IL-6 in a sensitive bioassay. A
transient appearance of circulating IL-6 was observed with peak levels between 3
and 6 h after the start of the hrTNF infusion. These peak levels correlated quite
well with the dose ofhrTNF administered (r = 0.86; p< 0.001). The maximal value
observed was 27.5 ng/ml IL-6 in a sample of a patient receiving 545 ug/m2 hrTNE
The combination of hrIFN-y (200 hg/m2) and hrTNF in the infusions resulted in
higher IL-6 levels than a comparable dose of hrTNF alone. A maximal value of 23.5
ng/ml IL-6 was observed in a patient receiving 205 hg/m2 hrTNF No IL-6 was
found in the plasma ofpatients during the 12-h infusion with hrIFN-y alone, except
for two borderline samples.
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